Kintegral Advisory LLC Sells 350 Shares of DaVita Inc. (NYSE:DVA)

Kintegral Advisory LLC decreased its holdings in DaVita Inc. (NYSE:DVA) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,508 shares of the company’s stock after selling 350 shares during the period. Kintegral Advisory LLC’s holdings in DaVita were worth $1,123,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Hussman Strategic Advisors Inc. raised its holdings in DaVita by 200.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company’s stock valued at $3,769,000 after acquiring an additional 16,800 shares during the period. Convergence Investment Partners LLC raised its stake in shares of DaVita by 33.2% during the 4th quarter. Convergence Investment Partners LLC now owns 11,389 shares of the company’s stock valued at $1,703,000 after purchasing an additional 2,836 shares during the period. Kentucky Retirement Systems Insurance Trust Fund raised its stake in shares of DaVita by 357.7% during the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 6,252 shares of the company’s stock valued at $935,000 after purchasing an additional 4,886 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in DaVita during the 4th quarter worth about $597,000. Finally, Venturi Wealth Management LLC boosted its stake in DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after purchasing an additional 152 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 2.5 %

Shares of NYSE DVA opened at $142.33 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The business has a 50-day moving average of $161.03 and a 200-day moving average of $158.00. The firm has a market capitalization of $11.39 billion, a price-to-earnings ratio of 13.25, a PEG ratio of 1.07 and a beta of 0.94. DaVita Inc. has a 12 month low of $120.78 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of recent analyst reports. Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $162.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.